In 73 adults (66 analysed) with newly diagnosed double-hit lymphoma, adding venetoclax to DA-EPOCH-R did not improve progression-free survival (median 7·7 vs 28·4 months; HR 1·13, p=0·75). On-treatment deaths 17% vs 3% led to early closure; 24-month overall survival 52% vs 72%.
RCTn = 73
Abramson et al. Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial